Finally, another piece of the puzzle emerges
As the medical field has received many technical innovations over the years, psychiatry and psychology has been left with surprisingly little. Now, with the EDOR test, a new and objective method for use in psychiatry and psychology research and clinical routine is available.
What is EDOR® Test and what does it do?
EDOR Test is a psychophysiological test using electrodermal reactions evoked by the brain to repeated neutral sound signals in order to analyse habituation patterns. Normally, reactions to repeated neutral stimuli gradually subside over time as the brain learns and builds a memory model of the events. In one patient group, reactions to the signals stops very quickly. These patients are classified as hyporeactive. Hyporeactivity in turn, have been shown to be a state associated with a more challenged course of disease in patients with depression.
Hyporeactivity in depression
Hyporeactivity is a state that is stable over time and remains after the depression is treated. Depressed hyporeactive patients have increased vulnerability to relapses in depression, suicide attempts, and suicide among adults.
Although hyporeactivity is associated to increased risks in depression, it is independent of common factors commonly used in psychiatric care, such as:
Symptoms and depth of depression (BDI, MADRS)
Traits (STAI-Trait) anxiety
Serotonin activity (5-HIAA in liquor)
Age and gender in adults
Language and cultural background
It functions as a biomarker, adding vital biological information to the overall assessment of the patient and should be used as a complement in this process. With this addition, a higher precision in the short and long -term planning of treatment and care is possible to achieve.
Emotra AB genomför riktad nyemission av aktier till garanter i samband med företrädesemissionen.
Emotra AB (”Emotra” eller ”Bolaget”) har slutfört den företrädesemission av units som beslutades av styrelsen den 22 april 2021... 20210617 - Emotra- PM - Riktad nyemission av aktier till garanter
Företrädesemissionen i Emotra AB blev kraftigt övertecknat till 176 procent och bolaget tillförs cirka 9,5 MSEK genom företrädesemissionen.
Den fullt garanterade företrädesemissionen om cirka 9,5 MSEK som offentliggjordes den 22 april 2021... 20210615 - Emotra- PM - Utfall i företrädesemission_
Emotra tecknar avtal med National Institute of Mental Health i USA
Efter en period av diskussioner har ett samarbetsavtal tecknats mellan National Institute of Mental Health (NIMH) i USA och Emotra. 210609 - Emotra- PM - Emotra tecknar avtal med NIMH
Mangold Insight har släppt uppdaterad analys av Emotra och VD Daniel Poté i VD-intervju hos Mangold Insight
Emotra AB (”Emotra” eller ”Bolaget”) meddelar att Mangold Insight har släppt en uppdaterad analys av Bolaget samt att Daniel Poté, VD i Emotra, har blivit intervjuad av Mangold Insight. 20210608 - Emotra- PM - VD-intervju och analys från Mangold Insight